CompletedNCT06791122

A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

Device studyAges 18+United States

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations: Imperial, United States · La Jolla, United States and 26 more locationsSee all locations and recruitment
Activities: Device procedures described in the protocol
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: January 23, 2025

Recruitment status: Completed
Enrollment listed in the registry: 262
Sponsor: Boehringer Ingelheim
Sponsor type: Unknown or unclear
Study type: Device
Intervention type: DEVICE
Study phase: Not clearly listed
Locations: United States
Age range: Over 18 Years
Official registry ID: NCT06791122
Official title: Show the full official title
A Multicenter, Pragmatic Study to Evaluate Clinical Effectiveness, Engagement With the Study App, Healthcare Resource Utilization, and Safety of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

Completed

Imperial · La Jolla · Oceanside

25 more locations

FAQ

Who is behind this study?

The study sponsor is Boehringer Ingelheim.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.